Babi Aisha, Menlibayeva Karashash, Bex Torekhan, Kuandykova Shynar, Akshulakov Serik
Hospital Management Department, National Centre for Neurosurgery, 34/1 Turan Avenue, Astana 010000, Kazakhstan.
Department of Vascular and Functional Neurosurgery, National Centre for Neurosurgery, 34/1 Turan Avenue, Astana 010000, Kazakhstan.
Biomedicines. 2023 Mar 13;11(3):886. doi: 10.3390/biomedicines11030886.
The study aimed to analyze the 5-year survival of adult patients with glial tumors and to define characteristics that are associated with the disease outcomes in Kazakhstan.
Medical records of patients that were surgically treated at the National Center for Neurosurgery during the 5-year period from 2016 to 2020 were collected retrospectively. Patients with a histologically confirmed diagnosis of diffuse astrocytic or oligodendroglial tumor type were included and their survival was assessed with life tables, Kaplan-Meier plot, and Cox regression using STATA 16 statistical software.
Almost half of the patients had glioblastoma. The 5-year survival rate of the whole sample was 45.93%. Among Grade 4 patients, 15.6% survived the 5-year mark. Differences in survival between grades 1-3 were not significant. Grade 1 patients demonstrated worse survival rates compared to Grade 2 patients (69% vs. 74%). Worse survival rates were observed among patients of Russian ethnicity and in rural residents.
The study described the unusual patterns in survival rates of glial tumor patients in Kazakhstan, pointing to the need for reassessment of diagnostic accuracy and resulting treatment of glial patients in Kazakhstan, and the need to introduce molecular and genetic parameters in tumor type classification. Moreover, the observed difference in survival of different ethnic groups and residents of rural and urban areas should be further investigated and addressed by healthcare professionals.
本研究旨在分析成年胶质肿瘤患者的5年生存率，并确定哈萨克斯坦与疾病预后相关的特征。
回顾性收集2016年至2020年期间在国家神经外科中心接受手术治疗的患者的医疗记录。纳入组织学确诊为弥漫性星形细胞瘤或少突胶质细胞瘤类型的患者，并使用STATA 16统计软件通过生命表、Kaplan-Meier曲线和Cox回归评估其生存率。
几乎一半的患者患有胶质母细胞瘤。整个样本的5年生存率为45.93%。在4级患者中，15.6%存活至5年。1-3级患者的生存率差异不显著。1级患者的生存率低于2级患者（69%对74%）。俄罗斯族患者和农村居民的生存率较差。
该研究描述了哈萨克斯坦胶质肿瘤患者生存率的异常模式，指出需要重新评估哈萨克斯坦胶质肿瘤患者的诊断准确性及后续治疗，以及在肿瘤类型分类中引入分子和基因参数的必要性。此外，医疗保健专业人员应进一步调查并解决观察到的不同种族群体以及农村和城市地区居民在生存率方面的差异。
